Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients

<span class="paragraphSection">Glioblastoma (GBM) is the most common and lethal type of primary tumor in the central nervous system. The median survival is literally less than 15 months.^{<a href="#CIT0001" class="reflinks">1</a>} However, the prognosis can be highly variable in the clinical situation. In addition to traditional prognostic factors, the importance of molecular signatures, such as mutation of isocitrate dehydrogenase (IDH) and promoter methylation of O⁶-DNA methylguanine-methyltransferase (MGMT), has drawn increasing attention in GBM management.^{<a href="#CIT0002" class="reflinks">2</a>,<a href="#CIT0003" class="reflinks">3</a>} Consequently, the 2016 World Health Organization (WHO) classification system has incorporated IDH mutation into the classification of GBM.^{<a href="#CIT0004" class="reflinks">4</a>} Despite knowledge of numerous valuable prognostic factors, there is still an urgent need to combine them for a comprehensive and individualized prediction.</span>

from Cancer via ola Kala on Inoreader http://ift.tt/2qovpll
via IFTTT